MetaStat, Inc. (OTCMKTS:MTST) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements of Certain Officers.
MetaStat, Inc. (OTCMKTS:MTST) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On April 25, 2017, Martin J. Driscoll provided MetaStat, Inc. (the “Company”) with notice of his resignation from the board of directors, effective immediately. The resignation of Mr. Driscoll was not due to any disagreement on any matter relating to the Company’s operations, policies or practices.
About MetaStat, Inc. (OTCMKTS:MTST)
MetaStat, Inc. is a pre-commercial molecular diagnostic company focused on the development and commercialization of diagnostics to provide oncologists and patients with clinically actionable information regarding the risk of systemic metastasis and adjuvant chemotherapy treatment decisions. The Company’s platform technologies are based on the identification of a pathway for the development of metastatic disease in epithelial-based solid tumors. It is developing two driver-based diagnostic product lines: MetaSite Breast and MenaCalc. Its MetaSite Breast and MenaCalc diagnostic product candidates are designed for patients based on their individual risk of metastasis. The MetaSite Breast test is applicable for early stage invasive breast cancer patients. The MenaCalc platform is a tissue-based quantitative immunofluorescence (QIF) assay applicable to a range of epithelial-based cancers, including breast, lung, colorectal and prostate. MetaStat, Inc. (OTCMKTS:MTST) Recent Trading Information
MetaStat, Inc. (OTCMKTS:MTST) closed its last trading session down -0.10 at 1.25 with 300 shares trading hands.
MetaStat, Inc. is a pre-commercial molecular diagnostic company focused on the development and commercialization of diagnostics to provide oncologists and patients with clinically actionable information regarding the risk of systemic metastasis and adjuvant chemotherapy treatment decisions. The Company’s platform technologies are based on the identification of a pathway for the development of metastatic disease in epithelial-based solid tumors. It is developing two driver-based diagnostic product lines: MetaSite Breast and MenaCalc. Its MetaSite Breast and MenaCalc diagnostic product candidates are designed for patients based on their individual risk of metastasis. The MetaSite Breast test is applicable for early stage invasive breast cancer patients. The MenaCalc platform is a tissue-based quantitative immunofluorescence (QIF) assay applicable to a range of epithelial-based cancers, including breast, lung, colorectal and prostate. MetaStat, Inc. (OTCMKTS:MTST) Recent Trading Information
MetaStat, Inc. (OTCMKTS:MTST) closed its last trading session down -0.10 at 1.25 with 300 shares trading hands.
